Editas Medicine (NASDAQ:EDIT) Upgraded by JonesTrading to “Buy” Rating

JonesTrading upgraded shares of Editas Medicine (NASDAQ:EDIT) from a hold rating to a buy rating in a research report report published on Tuesday,Benzinga reports. The firm currently has $8.00 price objective on the stock.

EDIT has been the topic of a number of other reports. Robert W. Baird set a $6.00 target price on shares of Editas Medicine in a report on Monday. Chardan Capital reiterated a “buy” rating and issued a $3.50 price target on shares of Editas Medicine in a research note on Monday. Weiss Ratings reissued a “sell (e+)” rating on shares of Editas Medicine in a research report on Wednesday, January 21st. Finally, TD Cowen reiterated a “buy” rating on shares of Editas Medicine in a research note on Monday. One investment analyst has rated the stock with a Strong Buy rating, five have issued a Buy rating, one has assigned a Hold rating and one has assigned a Sell rating to the stock. According to data from MarketBeat.com, the company has a consensus rating of “Moderate Buy” and a consensus price target of $5.30.

Editas Medicine Price Performance

Shares of NASDAQ EDIT opened at $2.64 on Tuesday. The business has a 50-day moving average of $2.02 and a 200-day moving average of $2.57. The stock has a market capitalization of $257.72 million, a price-to-earnings ratio of -1.40 and a beta of 2.16. Editas Medicine has a fifty-two week low of $0.91 and a fifty-two week high of $4.54.

Editas Medicine (NASDAQ:EDIT) last released its earnings results on Monday, March 9th. The company reported ($0.06) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.27) by $0.21. The business had revenue of $24.74 million for the quarter, compared to analyst estimates of $8.77 million. Editas Medicine had a negative return on equity of 376.20% and a negative net margin of 395.02%. On average, sell-side analysts expect that Editas Medicine will post -2.71 EPS for the current year.

Institutional Trading of Editas Medicine

Several hedge funds have recently added to or reduced their stakes in the company. Captrust Financial Advisors acquired a new stake in shares of Editas Medicine during the second quarter worth $26,000. StoneX Group Inc. acquired a new position in shares of Editas Medicine in the fourth quarter valued at about $33,000. Victory Capital Management Inc. acquired a new position in shares of Editas Medicine in the third quarter valued at about $36,000. Sei Investments Co. bought a new position in Editas Medicine during the third quarter worth about $46,000. Finally, Baader Bank Aktiengesellschaft acquired a new stake in Editas Medicine in the 3rd quarter worth about $50,000. 71.90% of the stock is owned by institutional investors and hedge funds.

Editas Medicine News Roundup

Here are the key news stories impacting Editas Medicine this week:

• Positive Sentiment: Q4 beat — Editas reported a narrower-than-expected loss (reported ($0.06) EPS vs. consensus ($0.27)) and revenue of $24.7M vs. estimates around $8.8M, driving optimism on near-term operational momentum. Editas Q4 Press Release
• Positive Sentiment: Pipeline progress — Editas reaffirmed that lead candidate EDIT-401 (preclinical >90% mean LDL-C reduction) remains on track for IND/CTA submission by mid‑2026 and a first‑in‑human trial in HeFH patients with early PoC data expected by year‑end 2026 — a material clinical catalyst. Business Update / EDIT-401
• Positive Sentiment: Analyst support — JonesTrading upgraded Editas to Buy with an $8 price target (large upside vs. current levels) and Chardan reaffirmed a Buy with a $3.50 target, increasing buy‑side attention and supporting the rally. Benzinga: Analyst Coverage
• Positive Sentiment: Cash runway — Management states cash runway into Q3 2027, which reduces near‑term financing risk while the company advances IND/CTA and early clinical plans. Cash Runway Disclosure
• Neutral Sentiment: Short‑interest data flagged as higher in March by some feeds, but reported figures show zero shares/NaN and a 0.0 days ratio — likely a data/reporting anomaly; no clear evidence of a substantive short squeeze.
• Negative Sentiment: Profitability and outlook remain weak — Editas is still unprofitable (negative net margin and ROE) and analysts expect a deep negative EPS for the year, meaning the stock remains dependent on clinical and revenue milestones rather than earnings. Zacks: Earnings Snapshot

Editas Medicine Company Profile

Editas Medicine is a clinical-stage biotechnology company focused on translating the power of gene editing into a new class of transformative genomic medicines. Founded in 2013 and headquartered in Cambridge, Massachusetts, the company leverages proprietary CRISPR/Cas9 and CRISPR/Cas12a (Cpf1) platforms to develop therapies aimed at correcting disease-causing genetic mutations. Editas Medicine’s research and development efforts span multiple therapeutic areas, including inherited retinal diseases, hemoglobinopathies, and oncology.

The company’s pipeline includes EDIT-101, a lead candidate designed to treat Leber congenital amaurosis type 10 (LCA10), which has entered early-stage clinical trials, and EDIT-301, targeting sickle cell disease and β-thalassemia using an ex vivo editing approach.